Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Camurus
CAMX
Camurus
Rising Global Scrutiny And Generic Competition Will Pressure Pharma Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
09 Jul 25
Updated
24 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 690.00
6.0% undervalued
intrinsic discount
24 Jul
SEK 648.50
Loading
1Y
-8.5%
7D
1.0%
Author's Valuation
SEK 690.0
6.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 690.0
6.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-286m
5b
2014
2017
2020
2023
2025
2026
2028
Revenue SEK 4.9b
Earnings SEK 2.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
28.56%
Pharma revenue growth rate
1.05%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
SEK 2.21b
Earnings '28
x
21.94x
PE Ratio '28
=
SEK 48.60b
Market Cap '28
SEK 48.60b
Market Cap '28
/
61.84m
No. shares '28
=
SEK 786.04
Share Price '28
SEK 786.04
Share Price '28
Discounted to 2025 @ 4.91% p.a.
=
SEK 680.68
Fair Value '25
